Zenome Genomic Data Marketplace
Sector: Quaternary sector · Industry: Biotechnology and genetic research · Organisation: Zenome · Maturity level: Concept
Zenome is a blockchain-based marketplace for genomic data that gives individuals control over their genetic information and ensures fair participation in monetization. Pharmaceutical companies can acquire genomic datasets without knowing the identity of data owners.
Documentation status
- Project status: Concept
- Evidence: Evidence high
- Editorial review: Ufuk Avci, 15 April 2026
Description
Zenome is a Russian biotech startup operating a blockchain-based marketplace for genomic data. Individuals can tokenise their genome data and sell it to pharmaceutical companies and research institutions without revealing their identity. The proprietary data transformation method preserves privacy while maintaining full analysis performance. Open-source components are available on GitHub.
Zenome addresses a fundamental problem in personalised medicine: the most valuable data — human genomes — are not fairly compensated to the data owners.
Perspectives
B2B — organisations perspective
Pharmaceutical and research companies gain access to genomic datasets without the ethical and legal hurdles of traditional biobanks.
B2C — consumers perspective
Individuals monetise their genome data fairly — they receive direct compensation instead of giving their data away for free to genomics companies.
Employees perspective
Bioinformaticians use the platform for privacy-compliant genome analyses without access to personal data.
Benefits
General
- Peer-to-peer network for genomic data without central intermediaries.
- Proprietary protocol for privacy-preserving analyses maintains anonymity.
- Open-source components on GitHub for transparency and auditability.
B2B — organisations
- Pharmaceutical companies gain access to genomic datasets without the ethical and legal hurdles of traditional biobanks.
- Research institutions can recruit cohorts directly and compensate them fairly.
B2C — consumers
- Individuals monetise their genome data fairly — direct compensation instead of free data provision.
- Anonymity is ensured through proprietary data transformation.
Employees
- Bioinformaticians conduct privacy-compliant genome analyses without access to personal data.
Challenges
General
- The project's public visibility is limited — the current development status is difficult to verify.
- Regulatory frameworks for blockchain-based genomic data marketplaces are lacking in most jurisdictions.
B2B — organisations
- Pharma partners require trust in the data quality and representativeness of cohorts on the platform.
B2C — consumers
- Users must organise genome sequencing themselves — no integrated sequencing service like Nebula.
Employees
- Validation of the proprietary privacy-preserving methodology requires independent audits.
Technology foundation
Proprietary peer-to-peer network protocol for genomic data, blockchain-based access control, open source on GitHub.
Implementation examples
Zenome
The genomic data market is dominated by a few large players who monetise user data without fair compensation. Zenome aims to reverse this model.
Zenome operates a blockchain-based P2P marketplace for genomic data under CEO Alexey Gorbachev.
Founded in 2017, Zenome enables individuals to sell their genetic data anonymously and fairly compensated via a P2P network to pharmaceutical companies and research institutions. A proprietary protocol transforms genome data for privacy-preserving analyses. Parts of the technology are available as open source on GitHub.
Fair compensation for data owners. Anonymisation through proprietary data transformation. Decentralised access without a central biobank.
Tags
Genomics, Data marketplace, Peer-to-peer, Open source, Data protection